Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, shares some insights into the importance of accurately defining precursor states in multiple myeloma and improving the diagnostic tools used to monitor disease progression. Dr Cerchione also highlights the value of using multiple parameters and incorporating cytogenetic information to better understand a patient’s risk of progression from monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma to active disease. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.